A $2 million phase 2 Small Business Technology Transfer (STTR) grant to optimize a promising new compound that has shown efficacy in preclinical studies against treatment-resistant multiple myeloma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results